Shaker A Mousa Selected Research

nano-diamino-tetrac

10/2021	Nano-Targeting of Thyrointegrin αvβ3 Receptor in Solid Tumors and Impact on Radiosensitization.
1/2020	NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
2/2017	Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac.
1/2017	Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac.
10/2016	Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shaker A Mousa Research Topics

Disease

166	Neoplasms (Cancer) 06/2022 - 01/2002
29	Thrombosis (Thrombus) 01/2021 - 01/2002
27	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2002
22	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2008
15	Hemorrhage 01/2022 - 08/2002
15	Inflammation (Inflammations) 01/2022 - 05/2005
14	Pancreatic Neoplasms (Pancreatic Cancer) 06/2022 - 06/2012
12	Cardiovascular Diseases (Cardiovascular Disease) 12/2022 - 05/2007
10	Glioblastoma (Glioblastoma Multiforme) 04/2022 - 07/2006
9	Carcinoma (Carcinomatosis) 01/2022 - 10/2004
8	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 05/2010
7	Neuroblastoma 01/2022 - 01/2008
7	Venous Thrombosis (Deep-Vein Thrombosis) 08/2009 - 01/2002
6	COVID-19 02/2022 - 01/2020
6	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 08/2021 - 09/2016
6	Body Weight (Weight, Body) 12/2020 - 01/2002
6	Diabetes Mellitus 05/2020 - 01/2009
6	Prostatic Neoplasms (Prostate Cancer) 05/2020 - 01/2012
6	Necrosis 01/2020 - 08/2014
6	Venous Thromboembolism 01/2020 - 04/2002
6	Obesity 01/2020 - 10/2010
6	Hypothyroidism 01/2018 - 07/2006
6	Macular Degeneration (Age-Related Maculopathy) 01/2013 - 01/2008
6	Thrombocytopenia (Thrombopenia) 04/2007 - 08/2002
5	Hypoxia (Hypoxemia) 01/2022 - 05/2009
5	Sickle Cell Anemia (Hemoglobin S Disease) 01/2022 - 08/2007
5	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021 - 05/2010
5	Type 2 Diabetes Mellitus (MODY) 12/2020 - 10/2010
5	Pain (Aches) 10/2020 - 08/2007
5	Colonic Neoplasms (Colon Cancer) 03/2020 - 07/2015
5	Colorectal Neoplasms (Colorectal Cancer) 03/2020 - 01/2018
5	Acute Coronary Syndrome 01/2015 - 01/2010
4	Infections 02/2022 - 01/2009
4	Hypercholesterolemia 01/2022 - 04/2005
4	Lung Neoplasms (Lung Cancer) 01/2022 - 04/2006
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2021 - 01/2011
4	Thyroid Neoplasms (Thyroid Cancer) 01/2021 - 05/2016
4	Carcinogenesis 05/2020 - 03/2009
4	Anemia 01/2020 - 01/2010
4	Pathologic Neovascularization 12/2019 - 10/2004
4	Diabetic Retinopathy (Retinopathy, Diabetic) 05/2019 - 01/2008
4	Glioma (Gliomas) 01/2019 - 07/2006
4	Osteoporosis 05/2018 - 01/2009

Drug/Important Bio-Agent (IBA)

51	IntegrinsIBA 04/2022 - 08/2002
46	Thyroid HormonesIBA 03/2022 - 07/2006
44	tetraiodothyroacetic acid (TA(4))IBA 04/2022 - 01/2008
30	Pharmaceutical PreparationsIBA 09/2021 - 08/2002
27	Thyroxine (Levothyroxine)FDA LinkGeneric 04/2022 - 07/2006
24	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2021 - 01/2002
23	AnticoagulantsIBA 01/2022 - 02/2002
20	Hormones (Hormone)IBA 04/2022 - 01/2008
20	Heparin (Liquaemin)FDA LinkGeneric 01/2022 - 02/2002
14	Proteins (Proteins, Gene)FDA Link 02/2022 - 01/2010
12	CytokinesIBA 01/2022 - 05/2007
12	Biological ProductsIBA 10/2021 - 11/2005
12	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2021 - 01/2008
11	AntioxidantsIBA 01/2022 - 11/2011
11	lipoprotein-associated coagulation inhibitor (TFPI)IBA 01/2021 - 02/2002
11	Cell Surface ReceptorsIBA 09/2018 - 07/2006
11	Tinzaparin (Innohep)FDA Link 03/2018 - 01/2002
10	Thyroid Hormone Receptors (Thyroid Hormone Receptor)IBA 04/2022 - 05/2009
10	Thromboplastin (Tissue Factor)IBA 01/2021 - 07/2003
9	Warfarin (Coumadin)FDA LinkGeneric 03/2015 - 02/2002
8	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 03/2022 - 12/2019
8	TriazolesIBA 03/2022 - 12/2019
8	thymoquinoneIBA 01/2022 - 01/2018
8	ResveratrolIBA 03/2020 - 01/2005
7	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/2022 - 02/2008
7	TeaIBA 01/2022 - 03/2009
7	LigandsIBA 10/2021 - 01/2008
7	LipidsIBA 12/2020 - 01/2009
7	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020 - 09/2003
7	ChitosanIBA 01/2020 - 01/2012
6	Hemoglobins (Hemoglobin)IBA 01/2022 - 01/2010
6	PolyphenolsIBA 01/2018 - 03/2009
5	Antineoplastic Agents (Antineoplastics)IBA 04/2022 - 01/2009
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2015
5	nano-diamino-tetracIBA 10/2021 - 10/2016
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 01/2005
5	Angiogenesis InhibitorsIBA 01/2018 - 01/2002
5	Estrogen ReceptorsIBA 08/2015 - 11/2009
5	Integrin alphaVbeta3IBA 01/2013 - 07/2006
5	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2010 - 01/2004
5	Hemostatics (Antihemorrhagics)IBA 01/2010 - 11/2005
4	Norepinephrine Plasma Membrane Transport Proteins (Norepinephrine Transporter)IBA 01/2022 - 01/2020
4	EnzymesIBA 01/2022 - 01/2004
4	benzylguanidineIBA 01/2022 - 01/2020
4	Interleukin-6 (Interleukin 6)IBA 11/2021 - 01/2018
4	Paclitaxel (Taxol)FDA LinkGeneric 11/2021 - 02/2011
4	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 01/2021 - 05/2016
4	Glycoproteins (Glycoprotein)IBA 01/2021 - 04/2002
4	Polylactic Acid-Polyglycolic Acid CopolymerIBA 01/2021 - 12/2013
4	Enoxaparin (Lovenox)FDA LinkGeneric 08/2019 - 12/2006
4	Retinaldehyde (Retinal)IBA 05/2019 - 03/2008
4	epigallocatechin gallate (epigallocatechin-3-gallate)IBA 01/2019 - 03/2009
4	Peptides (Polypeptides)IBA 01/2019 - 09/2003

Therapy/Procedure

60	Therapeutics 06/2022 - 04/2002
38	Drug Therapy (Chemotherapy) 06/2022 - 02/2002
8	Radiotherapy 01/2022 - 07/2003
4	Oral Administration 01/2020 - 01/2002